Treatment of Cervical Cancer

Introduction to Treatment Guidelines

The American College of Obstetricians and Gynecologists recommends that treatment of cervical cancer be tailored according to disease stage, with surgery recommended for early stages and concurrent chemoradiation for more advanced disease 1

For stage IA1 without lymphovascular space invasion, fertility-sparing options include cone biopsy with negative margins, while non-fertility-sparing options include extrafascial hysterectomy 1, 2
For stage IA1 with lymphovascular space invasion or 1-3 mm invasion, standard surgery includes simple hysterectomy or total hysterectomy, with external and interiliac lymphadenectomy recommended 2
For stage IA2, standard treatment includes hysterectomy with lymphadenectomy, while fertility preservation options include radical trachelectomy with pelvic lymph node dissection 1, 2
For early invasive disease (stages IB1, IIA1), treatment options include radical hysterectomy with pelvic lymphadenectomy or pelvic radiation therapy plus brachytherapy, with the choice depending on patient factors and institutional expertise 1, 2
For locally advanced disease (stages IB2-IIA2, IIB), standard treatment includes concurrent chemoradiation with external beam radiation, brachytherapy, and cisplatin-based chemotherapy, which significantly improves local control and overall survival compared to radiotherapy alone 1, 3

For concurrent chemoradiation, the standard regimen includes cisplatin-based chemotherapy, with a recommended dose of 40 mg/m² weekly or 50-75 mg/m² every 3-4 weeks 3

Fertility preservation should be considered for young women with early-stage disease, but is not recommended for small cell neuroendocrine tumors or minimal deviation adenocarcinoma 1
For pregnant women with cervical cancer, stage IA disease can be followed until the end of pregnancy, while invasive cancers require priority treatment during the first trimester 4
Pelvic lymphadenectomy is standard for most stages of cervical cancer, while para-aortic lymphadenectomy should be considered for larger tumors and suspected pelvic nodal disease 5

Regular surveillance is recommended, with follow-up every 3-4 months during the first 2 years, every 6 months for the following 3 years, and annually thereafter 4
Follow-up should include history-taking, clinical examination, assessment for treatment-related complications, and vaginal smears only if clinically indicated 4

Combined modality treatment has higher complication rates than either modality alone, while induction or neoadjuvant chemotherapy before radiotherapy increases radiotherapy-induced toxicity and the risk of treatment disruption 1, 2
Toxicity of radiochemotherapy is predominantly hematological and intestinal, and is greater than that of radiotherapy alone 3

The British Journal of Cancer recommends alternative dosing of 50-75 mg/m² every 3-4 weeks with 5-FU for cervical cancer treatment 6
The British Journal of Cancer suggests that brachytherapy at low dose rate remains the standard, and high-dose rate delivery shows no survival advantage 7
The British Journal of Cancer indicates that the total radiation dose and timing are more critical than adding upfront chemotherapy 7
External beam radiation to the pelvis (L4-L5 junction as upper limit) is a standard treatment approach 7
Brachytherapy applications (minimum 2) are a standard part of the treatment regimen 7

The British Journal of Cancer emphasizes the importance of completing radiation therapy within 50-55 days for optimal local control 7